Startup profile for Helix: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Helix funding, valuation and investors

Population genomics and clinical-research platform spun out of Illumina — consumer DNA marketplace.

Keep track of Helix

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series E

undisclosed · 2021

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · San Mateo, California

Investors in latest funding

Lead: Kleiner Perkins

Sources: latest funding Last verified: 2026-07-25

Overview

Helix is a population-genomics company spun out of Illumina that sequences consumer DNA and powers a marketplace of third-party health and ancestry apps built on its platform.

Why Helix is interesting

Raised $435M+ to pair sequencing with app ecosystem; a16z on cap table per investment list.

Product & use cases

Helix sequences consumer DNA and operates a marketplace where third-party apps deliver health, wellness, and ancestry insights on its genomics platform.

  • Consumer DNA sequencing as platform infrastructure
  • Third-party health and ancestry app marketplace
  • Clinical-grade sequencing for partner applications

Key facts

  • Series E (2021): Kleiner Perkins among lead investors; DFJ Growth, Warburg Pincus, and Temasek also in syndicate — Tracxn / Caplight
  • Spun out of Illumina; raised $435M+ to pair sequencing infrastructure with a consumer DNA app ecosystem

Funding history (newest first)

Series E

2021 undisclosed

Source: https://tracxn.com/d/companies/helix/

Investors in our directory

Funds linked from Helix's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Kleiner Perkins

Competitive landscape

Edge: Platform play vs. single-test DTC brands — spun out of Illumina with $435M+ raised.

Consumer genomics consolidated around a few brands. Helix's platform model depends on partner app ecosystem — 23andMe's troubles highlight sector risk.

  • 23andMe direct

    DTC genetics; Helix platform model vs. direct consumer brand.

  • AncestryDNA direct

    Consumer ancestry; Helix powers partner apps.

  • Color Health adjacent

    Population health genomics; different go-to-market.

Notable stories

  • Spun out of Illumina in 2015 — clinical-grade sequencing infrastructure play.
  • Raised $435M+ total across rounds; Kleiner Perkins led Series E (2021).

Industries

Healthtech Biotech & Life Sciences

FAQs about Helix

Practical answers founders, operators, and investors typically search for.

Sequences consumer DNA and powers a marketplace of third-party health, wellness, and ancestry apps.
a16z (/fund/andreessen-horowitz) and Kleiner Perkins (/fund/kleiner-perkins) among backers. Kleiner led Series E (2021).
23andMe is DTC brand; Helix is platform infrastructure for partner apps.
Spun out of Illumina in 2015.
Series E (2021); $435M+ total raised.
Sequencing fees and platform revenue from partner apps on its genomics infrastructure.
Platform play in consumer genomics — infrastructure rather than single-test brand.
No — remains private.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.